Search

Your search keyword '"Gao, Benjian"' showing total 2 results
Start Over Author "Gao, Benjian" Publisher dove press
2 results on '"Gao, Benjian"'

1. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma

Author

Gao,Benjian, Luo,Jia, Liu,Ying, Su,Song, Fu,Shaozhi, Yang,Xiaoli, Li,Bo, Gao,Benjian, Luo,Jia, Liu,Ying, Su,Song, Fu,Shaozhi, Yang,Xiaoli, and Li,Bo

Abstract

Benjian Gao,1– 3,* Jia Luo,4,* Ying Liu,1– 3,* Song Su,1– 3 Shaozhi Fu,4 Xiaoli Yang,1– 3 Bo Li1– 3 1Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China; 2Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan Province, People’s Republic of China; 3Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan Province, People’s Republic of China; 4Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaoli Yang; Bo LiDepartment of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Road, Luzhou, Sichuan, 646000, People’s Republic of ChinaTel +86-15086878251; +86-13518371998Email 344920646@qq.com; liboer2002@126.comBackground: The efficacy of systemic chemotherapy for hepatocellular carcinoma (HCC) is predominantly hampered by low accumulation in tumor tissue and the high systemic toxicity of anticancer drugs. In this study, we designed an in situ drug-loaded injectable thermosensitive hydrogel system for the simultaneous delivery of norcantharidin-loaded nanoparticles (NCTD-NPs) and doxorubicin (Dox) via intratumoral administration to HCC tumors.Methods: NCTD-NPs were prepared by the thin film dispersion method using PCEC polymers as the carrier. Then, NCTD-NPs and Dox were co-encapsulated in a thermosensitive hydrogel based on Pluronic F127 (PF127) to construct a dual drug-loaded hydrogel system. The rheological properties of the drug-loaded hydrogel were studied using a rheometer. Drug release of the drug-loaded hydrogel and cytotoxicity in HepG2 cells were evaluated in vitro. An H22 tumor-bearing mice model was used to assess th

Published
2021

2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Author

Gao B, Yang F, Zheng D, Hu S, Liu J, Liu H, Liu Y, Liu L, Wang R, Zhao Y, Cui C, Fang C, Yang J, Su S, Han Y, Yang X, and Li B

Abstract

Purpose: This study aimed to explore the clinical efficacy of transarterial chemoembolization (TACE) in combination with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) (triple therapy) compared to TACE alone (monotherapy) for advanced hepatocellular carcinoma (HCC)., Material and Methods: Data of consecutive advanced HCC patients receiving triple therapy or monotherapy at our center between January 2019 and December 2022 were collected and retrospectively analyzed. Propensity score matching (PSM) and subgroup analyses were performed to reduce the bias between the two groups. The primary outcomes of the study were the overall survival (OS) and progression-free survival (PFS). The secondary outcomes were the objective response rate (ORR) and disease control rate (DCR)., Results: A total of 104 patients were enrolled in this study: 41 in the triple therapy group and 63 in the monotherapy group. After PSM analysis, each group included 37 patients. The median OS and PFS were significantly longer in the triple therapy group than in the monotherapy group in the whole cohort (median OS, 18.8 vs 11.7 months, P = 0.022; median PFS, 10.5 vs 6.4 months, P = 0.012) and after PSM (median OS, 19.6 vs 12.5 months, P = 0.030; median PFS, 10.5 vs 6.7 months, P = 0.008). Furthermore, the treatment modality was an independent prognostic factor for OS (hazard ratio [HR]: 0.449, 95% confidence interval [CI]: 0.240-0.840, P = 0.012) and PFS (HR: 0.406, 95% CI: 0.231-0.713, P = 0.002) according to the multivariate cox regression analysis. A greater ORR was also observed in the triple therapy group (ORR: 56.7% vs 32.4%, P = 0.035). No significant difference was observed in DCR between the two groups (83.7% vs 72.9%, P = 0.259)., Conclusion: The triple therapy was superior to the monotherapy regarding OS, PFS, and ORR of advanced HCC patients., Competing Interests: The authors have no relevant financial or non-financial interests to disclose for this work., (© 2023 Gao et al.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results